BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.

SHEL teams with Modec, Unicamp and Shape Digital to use AI and data analysis to enhance safety and reduce risks on FPSO offshore vessels.

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Shoals Technologies (SHLS) points to a 25.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Helios Technologies, Inc (HLIO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HLIO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 142.3% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

RMAX remains a buy, as its solid agent network, stable revenues, and manageable debt position it for upside when the real estate market recovers. Share buybacks are a concrete near-term catalyst; if leverage drops below 3.5x, even conservative repurchases could drive an 8-18% upside in EPS. Dividend resumption is less likely in the short term due to weaker free cash flow, but remains a potential medium-term catalyst if cash generation improves.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exxon Mobil has a strong integrated business model that provides stability across commodity cycles. The company's earnings and revenue consistently exceed analyst expectations. Exxon Mobil offers a reliable dividend yield with a history of annual increases.

Amazon is lobbying the Indian government to ease its foreign investment rules to allow the U.S. company to buy products directly from Indian sellers to sell in overseas markets, four people with direct knowledge of the matter said.

PBR awards Halliburton and SLB $328 million in well services contracts to boost output at Brazil's massive Buzios pre-salt field.